The Promise and Threat of Precision Cancer Medicine
Barrett J. Rollins, MD, PhD,
Linde Family Professor of Medicine, Harvard Medical School
Chief Scientific Officer, Dana-Farber Cancer Institute
Anne Altmeyer, VP, Business Development, Head Negotiation, Oncology,
Dov Hass, Associate, Morgan. Lewis & Bockius LLP
Catherine Pickering, Head of Oncology Licensing, Global BD, Merck Serono SA
Dennis Purcell, Senior Managing Partner, Aisling Capital
Francis Kern, Senior Director of External Scientific Affairs, Daiichi Sankyo Inc.
Howard J. Fingert, Senior Medical Director, Business Development & Clinical Intelligence,
Ji Li, Vice President, Business Development and Licensing, Merck & Co., Inc.
John Gustofson, Senior Director, Venture and Early Stage Collaboration, AbbVie
Steven Tregay, Chief Executive Officer, Forma Therapeutics
Next Gen Immunotherapeutics
Mara Goldstein, Managing Director & Senior Biotechnology Analyst, Cantor Fitzgerald
Raffaele Baffa, Senior Director, Translational and Experimental Medicine, Sanofi Aventis SA
Gil Beyen, Chairman and CEO, Erytech Pharma
Greg Naeve, Head of Strategic Research Partnerships, Oncology, Pfizer
Jeff Abbey, President & CEO, Argos Therapeutics, Inc.
Marc Mansour, CEO, Immunovaccine Inc.
Paul Higham, Managing Director, immatics biotechnologies GmbH
Robert Petit, CSO, Advaxis Inc.
Gene & Cell Therapy
Maxim Jacobs, Senior Healthcare Analyst, Edison Group
Mike Rice, Senior Consultant, Defined Health
Mike Khan, CMO, Silence Therapeutics
Robert O. Dillman, Vice-President of Oncology, NeoStem, Inc.
Peshwa Madhusudan, Executive Vice President, Cellular Therapies, MaxCyte, Inc.
Peter Hoang, Senior Vice President Business Development & Strategy, Bellicum Pharmaceuticals, Inc.
Personalised Medicine & Diagnostiics
Rowan Chapman, Managing Director, Ventures, GE Healthcare
Stephan Brozak, Managing Partner and President, WBB Securities, LLC
Bernhard Sixt, President and CEO, ImmunID
Claudio Carini, Global Head of Immunology & Biomarkers, Pfizer
Lisa Ricciardi, SVP Corporate & Business Development, Foundation Medicine
Thomas H. Tulip, President and Chief Business Officer, Navidea Biopharmaceuticals
Beth Jacobs, Managing Partner, Excellentia Global Partners
Stuart Barich, Managing Director, Raymond James Financial, Inc.
Daniel Teper, CEO, Immune Pharmaceuticals Inc.
Jens Eckstein, President, S.R.One Limited
John DeYoung, Vice President, Worldwide Business Development, Pfizer
Philippe Mauberna, CFO, Nanobotix
Shakti Narayan, Sr. Director, Transactions, Johnson & Johnson Innovation Center
Todd Foley, Managing Director, MPM Capital
Public & Private Partnerships
Lee Greenberger, Chief Scientific Officer, The Leukemia and Lymphoma Society
O. Prem Das, Chief Business Development Officer, Dana-Farber Cancer Institute
Daniel Auclair, Vice President, Translational Research, The Multiple Myeloma Research Foundation
Darryl Mitteldorf, Executive Director, Global Prostate Cancer Alliance
Juan Carlos Lopez, Head of Academic Relations & Collaborations, Roche
Leigh Zawel, Site Head, New York and Boston Centers for Therapeutic Innovation, Pfizer
Louise Perkins, Chief Science Officer, Melanoma Research Alliance
Steven Young, President and COO, Addario Lung Cancer Medical Institute
For full list of 2015 participating speakers click HERE
Review the full list of 2014 Forum Speakers & Chairs >>
Presenting at the forum offers excellent opportunities to showcase activities and highlight investment and partnership opportunities. Biotech companies will be able to communicate investment and licensing opportunities. These are for both public and private companies. The audience is comprised of financial and industry investors. These are streamed 10 or 15 minute presentations.
Sachs forums are recognised as the leading international stage for those interested in investing in the biotech and life science industry and are highly transactional. They draw together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharmas. The New York forum provides the additional interaction with the academic/scientific and patient advocacy communities.
Sachs Associates has developed an extensive knowledge
of the key individuals operating within the European and global biotech
industry. This together with a growing reputation for excellence puts
Sachs Associates at the forefront of the industry and provides a powerful
tool by which to increase the position of your company in this market.